OVERVIEW OF ACTIVITY
Prostate cancer (PC) is the most frequently diagnosed cancer in men, with an estimated 233,000 new cases in 2014 in the United States. Although virtually all locally advanced or metastatic tumor sites are initially reliant on androgen stimulation for growth and respond to treatment with androgen deprivation therapy, inevitably resistance to hormone blockade develops, culminating in the recurrence of highly aggressive castration-resistant PC (CRPC). Recently published randomized, controlled studies focused specifically on this population have led to the emergence of novel therapeutic strategies for patients with CRPC and resulted in a paradigm shift to the multidisciplinary care of this disease. A number of pivotal data sets illustrating the benefits of several novel agents indicate that additional therapeutic options may soon be available that will warrant consideration for integration into PC care. The treatment landscape and available options for PC have thus broadened, making choices more challenging for many healthcare professionals and patients, and a once-stagnant systemic treatment algorithm, largely confined to medical or surgical castration, has evolved into delivery of cutting-edge antineoplastic therapy necessitating learning opportunities for urologists and medical oncologists. This CME program uses one-on-one interviews with 2 leading PC clinical investigators and faculty at a recent satellite symposium to discuss cases and questions submitted by attendees. This program will assist practicing clinicians in formulating up-to-date and appropriate clinical management strategies.

LEARNING OBJECTIVES

• Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve or pretreated CRPC, and use this information to guide treatment planning for these patients.
• Effectively apply evidence-based research findings in the determination of best-practice use of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.
• Consider available Phase III clinical trial data documenting the efficacy of radium-223 dichloride in patients with PC and bone metastases, and formulate strategies to appropriately use this recently approved radiopharmaceutical agent.
• Explore the emerging data and active research evaluating novel agents in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for their clinical activity.
• Counsel appropriately selected patients with biochemically recurrent, asymptomatic and symptomatic metastatic PC about availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity contains an audio component. To receive credit, the participant should review the CME information and listen to the MP3s.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Tomasz M Beer, MD
Grover C Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Hematology and Medical Oncology
Deputy Director, OHSU Knight Cancer Institute
Portland, Oregon

Contracted Research: Astellas, Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation.

A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Progenics Pharmaceuticals Inc, Sanofi.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc, Exelixis Inc, Millennium: The Takeda Oncology Company, Sanofi and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: June 2014
Expiration date: June 2015